Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SI
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study | Semantic Scholar
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial - The Lancet Oncology
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
Full article: Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR - Annals of Oncology
Children | Free Full-Text | High-Risk Neuroblastoma Treatment Review
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial - The Lancet Oncology
Trial profile COJEC=cisplatin, carboplatin, cyclophosphamide,... | Download Scientific Diagram
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
A study looking at treatment for high risk neuroblastoma (HR/NBL2/SIOPEN) | Cancer Research UK
IJMS | Free Full-Text | MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
JOURNAL CLUB HIGH-DOSE RAPID AND STANDARD INDUCTION CHEMOTHERAPY FOR PATIENTS AGED OVER 1 YEAR WITH STAGE 4 NEUROBLASTOMA: A RANDOMISED TRIAL † Lancet. - ppt download
Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | bioRxiv
Neuroblastoma - Chung - 2021 - Pediatric Blood & Cancer - Wiley Online Library
![PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/61dfb3a5ee37540ef03aaa30a65508f621b16f2b/4-Table1-1.png "PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar")
PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study
Thieme E-Books & E-Journals -
Clinical impact of primary tumour 123ImIBG response to induction chemotherapy in children with high-risk neuroblastoma | International Journal of Clinical Oncology
High frequency of viridians group streptococci bacteremia in pediatric neuroblastoma high-risk patients during induction chemotherapy | Scientific Reports
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. - Abstract - Europe PMC
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
